Nona Biosciences | LinkedIn (original) (raw)

Biotechnology Research

Cambridge, Massachusetts 5,580 followers

Empower Global Biotherapeutic Innovation

• Access all 36 employees

About us

Nona Biosciences is a global biotechnology company committed to providing a total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody discovery services range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging the advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs by diversified partnership strategies including co-discovery, platform and antibody discovery, and platform license. The values of the antibody discovery platforms and flexible partnership models have been well validated by more than 50 industry and academic partners within over 200 projects.

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Cambridge, Massachusetts

Type

Public Company

Founded

2022

Locations

Employees at Nona Biosciences

Updates

• 
  5,580 followers
  3d Edited
  🌟 Unlock the Future of CAR-T Therapy with Nona Biosciences! 🌟 Are you looking to stay at the cutting edge of cancer treatment advancements? Our latest white paper dives deep into how Nona Biosciences is transforming CAR-T therapy using state-of-the-art, fully human heavy chain antibodies (HCAbs) for superior efficacy and safety. Highlights of our innovations: - 𝗡𝗼𝗻𝗮𝗖𝗔𝗥™ 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆: Leverages fully human HCAbs to reduce immunogenicity and maximize therapeutic impact. - 𝗡𝗼𝗻𝗮𝗖𝗮𝗿𝗙𝘅™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺: Pioneering direct CAR-function-based HCAb screening for faster, more efficient development. - 𝗕𝗲𝗮𝗰𝗼𝗻® 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆: Achieve single-day antibody discovery, optimizing labor and throughput. - 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗜𝗻 𝗩𝗶𝘁𝗿𝗼 𝗖𝗵𝗮𝗿𝗮𝗰𝘁𝗲𝗿𝗶𝘇𝗮𝘁𝗶𝗼𝗻: Ensures robust, high-performance CAR-T cell therapy. Ready to explore the science behind these breakthroughs? Download the full white paper to learn more about our integrated technologies and how we're driving the future of CAR-T therapies. 👉 https://lnkd.in/eNiMxrrF #HCAb #heavychainonly #CARTcell #CART #CARTTherapy #Biotechnology #AntibodyDiscovery #CancerTreatment #Innovation
  CAR-Based Antibody Discovery Brochure - Nona Biosciences https://nonabio.com
• 
  5,580 followers
  4d Edited
  💡TCRm antibodies are revolutionizing cancer immunotherapy by combining T-cell receptor precision with antibody versatility, enabling the targeting of a wider range of intracellular antigens. 💡These antibodies can recognize antigens presented by MHC molecules, achieving subnanomolar affinity for greater therapeutic impact. With mechanisms like ADCC, CDC, and peptide-MHC targeting, TCRm antibodies enhance tumor cell destruction. 💡They also provide antibody-like stability and a long half-life, while being easier to manufacture than traditional TCR-based therapies, making them scalable for large-scale application. Nona Biosciences is at the forefront of this innovation, advancing cancer treatment with highly specific and promising TCRm designs. Learn more: https://lnkd.in/eT-_VkKp
  
• The moment is finally here! Join us at Booth #417 and then head over to the Town & Country Room D at 12:30 PM to discover our groundbreaking Novel Enzyme Cleavable Linker for the Development of Next-Gen ADCs against Solid Tumors. Whether you have just a brief moment to drop by or want to engage in deeper conversation, we're here to explore how we can help you advance your next ADC therapeutic. Looking forward to seeing you there #antibodies #drugdevelopment #antibodydiscovery #HCAb #heavychainantibodies
  
• TCRm antibodies represent a breakthrough in cancer immunotherapy, combining T-cell receptor specificity with antibody properties to target a wider range of intracellular antigens. Unlike traditional therapies, TCRm antibodies offer unique advantages: - 𝗕𝗿𝗼𝗮𝗱𝗲𝗿 𝗔𝗻𝘁𝗶𝗴𝗲𝗻 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴: Recognize intracellular antigens presented by MHC molecules, expanding beyond surface targets. - 𝗛𝗶𝗴𝗵𝗲𝗿 𝗔𝗳𝗳𝗶𝗻𝗶𝘁𝘆: Achieve subnanomolar affinity, potentially enhancing therapeutic effectiveness. - 𝗠𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀 𝗼𝗳 𝗔𝗰𝘁𝗶𝗼𝗻 (𝗠𝗢𝗔): Enable tumor cell killing through ADCC, CDC, and specific peptide-MHC recognition. - 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆-𝗟𝗶𝗸𝗲 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗹𝗼𝗴𝘆: Offer a long half-life and stability for sustained action. - 𝗦𝗰𝗮𝗹𝗮𝗯𝗹𝗲 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻: Easier to manufacture than TCR-based therapies, ideal for large-scale applications. Nona Biosciences' TCRm antibodies are leading the way with innovative design and high specificity, holding strong promise for advancing cancer treatment.💡 Learn more: https://lnkd.in/eT-_VkKp #TCRm #TCRmimic #antibodies #HCAb #CancerResearch #Immunotherapy #Biotech
  TCR Mimic Antibody - Nona Biosciences https://nonabio.com
• 
  5,580 followers
  2w Edited
  🌟 Join Nona Biosciences at World ADC 2024! 🌟 📍 Booth #417 🗓️ Presentation: Wednesday, November 6th ⏰ Time: 12:30 PM 🎤 Speaker: Musheng Bao, Vice President, Head of Biology Topic: Discovery and Preclinical Validation of a Novel Enzyme Cleavable Linker for Development of Next-Gen ADC Against Solid Tumors Summary: Tackling the challenges of poor drug penetration and high tumor heterogeneity in ADC and other biologics, Nona Bioscience has developed a groundbreaking linker technology. This innovative linker leverages a unique cleavage mechanism, utilizing an enzyme abundant in the tumor microenvironment (TME) of solid tumors. Paired with our proprietary payloads, it enables efficient, tumor-specific release, independent of internalization. Our preclinical data shows promising efficacy and safety improvements with this linker-payload system. Don’t miss this opportunity to learn about the next generation of targeted cancer therapies!
  
• An overview of the 𝗛𝗖𝗔𝗯 𝗣𝗟𝗨𝗦™ by Nona Biosciences💡 HCAb PLUS™ is the world’s first fully human heavy chain-only antibody (HCAb) platform, clinically validated and experimentally proven, and enables breakthrough in therapeutic modalities. 𝗞𝗲𝘆 𝗙𝗲𝗮𝘁𝘂𝗿𝗲𝘀: 🌟 HBICE® Technology — Unleashing bispecifics, multispecifics, immunocytokines, and other cutting-edge formats with enhanced structure, size reduction, and chain simplicity. 🌟 Breakthrough Therapeutic Modalities — Designed for powerful applications in ADCs, RDCs, PROTACs, and other areas demanding precision, efficiency, and adaptability. 🌟 Superior Performance in CAR Therapies — HCAbs from our HCAb Harbour Mice® deliver reduced immunogenicity, high solubility, tissue penetration, and conjugation benefits, ideal for advanced CAR-based cell therapies. 🌟 Pioneering mRNA Therapies & Targeted Delivery — The compact size and structural benefits of HCAbs enable next-level mRNA designs and LNP modifications, opening up new avenues in targeted treatments. Nona Biosciences is leading the way with highly stable, low-immunogenic, fully human HCAbs for breakthrough therapies. Explore the future of therapeutic innovation with HCAb PLUS™: https://lnkd.in/ecfYaq5u #antibodies #fullyhuman #fullyhumanantibodies #HCAb #heavychainonlyantibodies #heavychainantibodies #nextgentherapeutics #Therapeutics #NonaBiosciences #HCAbPLUS #BiotechInnovation #ImmuneTherapy #ADC #mRNAtherapey #CARTtherapy #CART
  HCAb Plus - Nona Biosciences https://nonabio.com
• 
  5,580 followers
  3w Edited
  𝐆𝐞𝐭 𝐊𝐞𝐲 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐨𝐧 𝐁𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 (𝐛𝐬𝐀𝐛𝐬) 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐖𝐢𝐭𝐡 𝐎𝐮𝐫 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐀𝐬𝐬𝐚𝐲 Bispecific antibodies are engineered to bind two different antigens simultaneously, enabling more precise therapeutic interventions. This unique mechanism allows for innovative treatments in fields like oncology and immunotherapy, offering new hope for difficult-to-treat conditions. 💡 𝐇𝐨𝐰 𝐜𝐚𝐧 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐚𝐬𝐬𝐚𝐲 𝐜𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐞 𝐭𝐨 𝐭𝐡𝐞 𝐁𝐬𝐀𝐛 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐩𝐫𝐨𝐜𝐞𝐬𝐬? 🟧 Early risk identification: Developability assessment uncovers potential challenges such as stability, immunogenicity, and manufacturability issues early in the development process. 🔍 🔵 Increased success rates: Identifying risks upfront reduces development failures, allowing only the most promising bsAb candidates to advance, boosting the chances of creating safe, effective therapies. ✅ Learn more: https://lnkd.in/eQ2uhNrD #BispecificAntibodies #DevelopabilityAssay #Biotech #Oncology #Immunotherapy #DrugDevelopment #Pharma #PrecisionMedicine #Biologics #InnovativeTherapies #HealthcareInnovation
  

Join now to see what you are missing

Join now

Similar pages

• Delphia Therapeutics Biotechnology Research Cambridge, Massachusetts
• Quiver Bioscience Biotechnology Research Cambridge, MA
• Myrobalan Therapeutics Biotechnology Research Medford, Massachusetts
• Nuvalent, Inc. Biotechnology Research Cambridge, Massachusetts
• Avalyn Pharma Biotechnology Research Cambridge, Massachusetts
• Seaport Therapeutics Biotechnology Research Boston, MA
• Pledge Therapeutics Biotechnology Research Canton, MA
• Fable Therapeutics Biotechnology Research Boston, Massachusetts
• KalVista Pharmaceuticals, Inc. Biotechnology Research Cambridge, Massachusetts
• AIRNA Biotechnology Research Cambridge, MA